rethinkTHC Search
Menu
Study breakdown

Cannabis May Help Protect the Gut Lining During Cancer Treatment

ReviewPreliminary evidence
The takeaway

Medicinal cannabis shows potential for managing mucositis and its cascading symptoms during cancer therapy by targeting inflammation, barrier function, and microbial balance in the gut.

Oncology professionals exploring supportive care options; cancer patients dealing with gut-related treatment side effects.

Mucositis drives a cascade of symptoms: diarrhea, nausea, infection, fatigue, depression, and insomnia

What the researchers found

The endocannabinoid system is densely distributed throughout the gut and modulates mucosal barrier integrity, inflammation, and microbial balance. Cannabis-based interventions could theoretically address mucositis and its downstream symptoms including diarrhea, nausea, infection, malnutrition, fatigue, depression, and insomnia through these interconnected pathways.

Why it matters

Mucositis affects up to 100% of patients receiving certain cancer treatments and drives a cascade of debilitating symptoms. Current management treats each symptom in isolation. Cannabis's multi-target action on the gut endocannabinoid system could address the root cause rather than individual symptoms.

The numbers in context

Mucositis contributes to diarrhea, nausea, vomiting, infection, malnutrition, fatigue, depression, and insomnia in cancer patients. The endocannabinoid system modulates motility, inflammation, pain signaling, and barrier function throughout the gastrointestinal tract.

How the study worked

Narrative review outlining the biological rationale for medicinal cannabis in managing cancer therapy-induced mucositis. Synthesizes evidence on the endocannabinoid system in gut function, documented effects of cannabis on gastrointestinal symptoms, and the cascade of symptoms linked to mucosal barrier breakdown.

What this study cannot tell us

This is a rationale paper, not a clinical study. No controlled trial data specifically test cannabis for mucositis prevention. The theoretical framework, while biologically plausible, requires clinical validation.

How to read the evidence

Preliminary: well-reasoned biological rationale supported by preclinical evidence, but lacks clinical trial data specific to cannabis and mucositis.

When this study was published

2024 review.

The bigger picture

Cancer supportive care has traditionally taken a "whack-a-mole" approach to side effects. Understanding mucositis as a driver of multiple downstream symptoms, and cannabis as a potential upstream intervention, could transform how we think about managing cancer treatment toxicity.

Questions still open

  • Would prophylactic cannabis use before chemotherapy reduce mucositis incidence? Which cannabinoid formulations would best target gut mucosal protection? Could cannabis interfere with cancer treatment efficacy while protecting the gut?

Common questions

What is mucositis?
Mucositis is the breakdown of the mucosal lining of the digestive tract caused by chemotherapy or radiation. It causes pain, ulcers, and barrier dysfunction that allows bacteria to enter the bloodstream and triggers a chain of other symptoms.
How could cannabis help with mucositis?
The endocannabinoid system is densely present in the gut and regulates inflammation, barrier integrity, motility, and pain signaling. Cannabis compounds interact with this system and could theoretically protect or repair the mucosal barrier during cancer treatment.

Read the original research

Supporting gut health with medicinal cannabis in people with advanced cancer: potential benefits and challenges.

British journal of cancer, 130(1), 19-30

Citation

Wardill, Hannah R; Wooley, Luke T; Bellas, Olivia M; Cao, Katrina; Cross, Courtney B; van Dyk, Madele; Kichenadasse, Ganessan; Bowen, Joanne M; Zannettino, Andrew C W; Shakib, Sepehr; Crawford, Gregory B; Boublik, Jaroslav; Davis, Mellar M; Smid, Scott D; Price, Timothy J. (2024). Supporting gut health with medicinal cannabis in people with advanced cancer: potential benefits and challenges.. British journal of cancer, 130(1), 19-30. https://doi.org/10.1038/s41416-023-02466-w

Explore the wider topic